Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 2
2013 1
2014 1
2016 1
2017 2
2019 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses.
Yang Z, Rajendran S, Spires V, Poirson B, Gururajan M, Lin Z, Arbanas J, Krystek S, Loy J, Cheng Y, Carl S, Pace S, Wang Y, Mehl J, Xu S, Vasudevan K, Broz M, Lehman-McKeeman L, Morin P, Graziano RF. Yang Z, et al. Among authors: xu s. Drug Metab Dispos. 2022 Jul;50(7):898-908. doi: 10.1124/dmd.121.000799. Epub 2022 May 11. Drug Metab Dispos. 2022. PMID: 35545256
The membrane organization of leukotriene synthesis.
Mandal AK, Skoch J, Bacskai BJ, Hyman BT, Christmas P, Miller D, Yamin TT, Xu S, Wisniewski D, Evans JF, Soberman RJ. Mandal AK, et al. Among authors: xu s. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6587-92. doi: 10.1073/pnas.0308523101. Epub 2004 Apr 14. Proc Natl Acad Sci U S A. 2004. PMID: 15084748 Free PMC article.
Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein.
Yang Z, Loy J, Poirson B, Dai Y, Rajendran S, Xu S, Spires V, Gururajan M, Lin Z, Arbanas J, Carl S, Pace S, Wang Y, Mehl J, Vasudevan K, Spires T, Novosiadly R, Coker S, Perez R, Covello K, Morin P, Graziano R, Broz M, Lehman-McKeeman L. Yang Z, et al. Among authors: xu s. Front Pharmacol. 2022 Jun 20;13:829063. doi: 10.3389/fphar.2022.829063. eCollection 2022. Front Pharmacol. 2022. PMID: 35795558 Free PMC article.
Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.
Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW. Ferguson AD, et al. Among authors: xu s. Science. 2007 Jul 27;317(5837):510-2. doi: 10.1126/science.1144346. Epub 2007 Jun 28. Science. 2007. PMID: 17600184
Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
Shi GQ, Dropinski JF, McKeever BM, Xu S, Becker JW, Berger JP, MacNaul KL, Elbrecht A, Zhou G, Doebber TW, Wang P, Chao YS, Forrest M, Heck JV, Moller DE, Jones AB. Shi GQ, et al. Among authors: xu s. J Med Chem. 2005 Jun 30;48(13):4457-68. doi: 10.1021/jm0502135. J Med Chem. 2005. PMID: 15974597
15 results